See analyst estimates and all valuation multiples for Regenerative Medicine
Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
---|---|---|---|
$118B | 10.3x | 36.5x | |
$10.8B | 3.6x | 14.0x | |
$4.2B | 13.2x | 32.0x | |
$3.7B | 10.6x | 27.9x | |
$3.6B | 90.8x | -7.8x | |
$2.4B | 665.8x | -62.3x | |
$2.2B | 3.8x | 34.0x | |
$2.1B | 7.9x | 32.4x | |
$1.5B | n/a | n/a | |
$1.4B | 65.6x | -48.2x | |
$1.1B | 18.7x | -2.6x | |
$1.0B | 1717.3x | -41.2x | |
$940M | 2.6x | 12.1x | |
$872M | 15.4x | -1.9x | |
$624M | 1.3x | 12.3x | |
$582M | 2.9x | 26.3x | |
$534M | 7.6x | 27.1x | |
$471M | 16.7x | -2.9x | |
$440M | n/a | n/a | |
$428M | 12.0x | 24.4x | |
$378M | 5.5x | -22.2x | |
$347M | 85.9x | n/a | |
$303M | 250.3x | n/a | |
$288M | n/a | n/a | |
$237M | 2458.9x | -1.4x | |
$196M | 24.4x | -8.3x | |
$186M | 0.6x | n/a | |
$175M | 28.6x | -54.6x | |
$171M | n/a | n/a | |
$154M | 5.4x | 11.0x | |
$132M | 1.1x | 17.8x | |
$122M | 2.3x | 39.4x | |
$119M | n/a | n/a | |
$109M | 4.1x | -8.9x | |
$89.9M | n/a | n/a | |
$71.2M | n/a | -5.1x | |
$63.2M | n/a | n/a | |
$51.9M | 193.3x | -0.2x | |
$48.3M | 35.2x | n/a | |
$24.3M | n/a | n/a | |
$23.0M | n/a | n/a | |
$20.7M | 5.2x | n/a | |
$15.3M | 20.4x | -3.1x | |
$9.8M | 1.7x | n/a | |
$9.5M | 4.6x | n/a | |
-$161M | -2.7x | 0.8x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Regenerative Medicine